Major Depressive Disorder (MDD), particularly its treatment-resistant form, represents a substantial burden on global public health, characterized by low remission rates with conventional monoaminergic pharmacotherapy. The paradigm shift toward glutamatergic modulation has identified the N-methyl-D-aspartate (NMDA) receptor as a critical target for rapid-acting antidepressants. Nitrous oxide...
Psilocybin, an indoleamine alkaloid derived from various fungal species, is the subject of renewed, rigorous investigation for its therapeutic potential in psychiatry. This compound, a prodrug for the active metabolite psilocin, functions primarily as a partial agonist at the serotonin 2A (5-HT2A) receptor. Its administration within a structured psychotherapeutic context is associated with...
Schizophrenia remains challenging to fully comprehend due to insufficient attention to its characteristic overall pattern, or "Gestalt," which defines its psychopathological structure. Schizophrenia is a chronic psychiatric condition influenced by diverse genetic and neurobiological factors impacting early brain development. It manifests through psychotic symptoms including hallucinations,...